Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.

MLA

Mohammadi, Mahmoud, et al. “Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.” Targeted Oncology, vol. 18, no. 3, May 2023, pp. 415–23. EBSCOhost, https://doi.org/10.1007/s11523-023-00960-y.

APA

Mohammadi, M., IJzerman, N. S., Hollander, D. den, Bleckman, R. F., Oosten, A. W., Desar, I. M. E., Reyners, A. K. L., Steeghs, N., & Gelderblom, H. (2023). Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data. Targeted Oncology, 18(3), 415–423. https://doi.org/10.1007/s11523-023-00960-y

Chicago

Mohammadi, Mahmoud, Nikki S IJzerman, Dide den Hollander, Roos F Bleckman, Astrid W Oosten, Ingrid M E Desar, An K L Reyners, Neeltje Steeghs, and Hans Gelderblom. 2023. “Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data.” Targeted Oncology 18 (3): 415–23. doi:10.1007/s11523-023-00960-y.